A number of other equities research analysts also recently weighed in on XENT. BidaskClub downgraded Intersect ENT from a strong-buy rating to a buy rating in a report on Tuesday, July 25th. Zacks Investment Research raised Intersect ENT from a sell rating to a hold rating in a research note on Wednesday, July 26th. Northland Securities reissued a hold rating and issued a $25.00 price objective on shares of Intersect ENT in a research note on Wednesday, August 2nd. Deutsche Bank AG set a $31.00 price objective on Intersect ENT and gave the company a buy rating in a research note on Wednesday, August 2nd. Finally, Canaccord Genuity reissued a buy rating and issued a $32.00 price objective on shares of Intersect ENT in a research note on Wednesday, August 2nd. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $30.88.
Shares of Intersect ENT (XENT) traded down $0.35 during midday trading on Tuesday, reaching $28.55. The company’s stock had a trading volume of 149,600 shares, compared to its average volume of 292,422. Intersect ENT has a 52-week low of $9.20 and a 52-week high of $33.25.
Intersect ENT (NASDAQ:XENT) last posted its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.05. The firm had revenue of $22.31 million during the quarter, compared to the consensus estimate of $21.53 million. Intersect ENT had a negative return on equity of 15.96% and a negative net margin of 19.81%. The business’s quarterly revenue was up 20.8% on a year-over-year basis. During the same period last year, the company earned ($0.22) earnings per share. equities research analysts predict that Intersect ENT will post -0.62 earnings per share for the current year.
In other Intersect ENT news, CFO Jeryl L. Hilleman sold 12,833 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $27.78, for a total transaction of $356,500.74. Following the sale, the chief financial officer now directly owns 27,833 shares in the company, valued at approximately $773,200.74. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Richard E. Kaufman sold 22,425 shares of the stock in a transaction on Monday, August 28th. The shares were sold at an average price of $30.22, for a total value of $677,683.50. Following the sale, the chief operating officer now owns 149,821 shares in the company, valued at $4,527,590.62. The disclosure for this sale can be found here. Insiders have sold a total of 115,363 shares of company stock valued at $3,406,647 in the last ninety days. 13.70% of the stock is currently owned by corporate insiders.
Large investors have recently bought and sold shares of the business. Legal & General Group Plc increased its holdings in shares of Intersect ENT by 3.8% in the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock worth $193,000 after purchasing an additional 255 shares during the last quarter. American International Group Inc. grew its position in Intersect ENT by 7.1% in the first quarter. American International Group Inc. now owns 15,704 shares of the medical equipment provider’s stock worth $269,000 after acquiring an additional 1,037 shares in the last quarter. Voya Investment Management LLC grew its position in Intersect ENT by 9.7% in the second quarter. Voya Investment Management LLC now owns 12,724 shares of the medical equipment provider’s stock worth $356,000 after acquiring an additional 1,128 shares in the last quarter. Rhumbline Advisers grew its position in Intersect ENT by 5.9% in the second quarter. Rhumbline Advisers now owns 29,396 shares of the medical equipment provider’s stock worth $822,000 after acquiring an additional 1,625 shares in the last quarter. Finally, EAM Investors LLC grew its position in Intersect ENT by 1.1% in the third quarter. EAM Investors LLC now owns 164,267 shares of the medical equipment provider’s stock worth $5,117,000 after acquiring an additional 1,776 shares in the last quarter. 87.22% of the stock is currently owned by institutional investors and hedge funds.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with our FREE daily email newsletter.